Jiao Chenwei, Jiao Xiaohu, Zhu Anzhi, Ge Juntao, Xu Xiaoqing
Department of Pediatric Surgery, Shandong Provincial Hospital affiliated to Shandong University, Jinan, China.
Department of Surgery, Baoji Hospital affiliated to Xi'an Medical University, Baoji, China.
J Pediatr Surg. 2017 Apr;52(4):618-624. doi: 10.1016/j.jpedsurg.2016.09.070. Epub 2016 Oct 14.
The aim of this study is to identify the diagnostic values of serum exosomal miRNA-34s of patients with HB in a large Asian group and explore the prognostic value of the exosomal miRNA-34s panel compared with other risk factors.
We retrospectively reviewed 89 children with HB. Among these patients, 63 patients were included as training group to build the diagnostic model for HB. 26 patients were defined as the validation group. The expressions of miRNA-34s were detected by real-time PCR. The comparison of diagnostic and prognostic performance of serum exosomal miRNA-34s was measured using the area under ROC curve (AUC).
For patients in the training group, expression of miRNA-34a, miRNA-34b and miRNA-34c was significantly lower in patients with HB compared with control group in serum exosomes. Between HB training group and the control group, exosomal miRNA-34a, miRNA-34b and miRNA-34c had no significant differences compared with the AFP level in diagnosing HB. The performance of the exosomal miRNA-34s panel in differentiating the HB training group from the control group was superior to the AFP level. The value of the exosomal miRNA-34s panel in predicting prognosis of patients with HB was superior to other risk factors in both training group and validation group.
In this study, we found that the expression of exosomal miRNA-34a, miRNA-34b and miRNA-34c was significantly lower in patients with HB compared with the control group, and we confirmed the exosomal miRNA-34s panel could be defined as a diagnostic and prognostic biomarker for patients with HB.
Level II.
Retrospective Study.
本研究旨在确定亚洲大型队列中乙型肝炎（HB）患者血清外泌体miRNA - 34s的诊断价值，并探讨外泌体miRNA - 34s组合与其他危险因素相比的预后价值。
我们回顾性分析了89例HB患儿。其中，63例患者作为训练组构建HB诊断模型，26例患者定义为验证组。采用实时PCR检测miRNA - 34s的表达。使用ROC曲线下面积（AUC）衡量血清外泌体miRNA - 34s的诊断和预后性能。
在训练组患者中，血清外泌体中HB患者的miRNA - 34a、miRNA - 34b和miRNA - 34c表达明显低于对照组。在HB训练组和对照组之间，外泌体miRNA - 34a、miRNA - 34b和miRNA - 34c在诊断HB时与甲胎蛋白（AFP）水平相比无显著差异。外泌体miRNA - 34s组合区分HB训练组和对照组的性能优于AFP水平。外泌体miRNA - 34s组合在预测HB患者预后方面在训练组和验证组均优于其他危险因素。
在本研究中，我们发现HB患者血清外泌体中miRNA - 34a、miRNA - 34b和miRNA - 34c的表达明显低于对照组，并证实外泌体miRNA - 34s组合可被定义为HB患者的诊断和预后生物标志物。
二级。
回顾性研究。
